Geneva has been selected to support a monoclonal antibody protocol under this public-private partnership at two military treatment facilities. TACOMA, WA – The Geneva Foundation (Geneva) announces today it has entered into a Cooperative Research and Development Agreement (CRADA) to conduct clinical trials at two military treatment facilities under the Accelerating COVID-19 Therapeutic Interventions
The Geneva Foundation is partnering with NCI scientists and the U.S. Army on two investigational grants for breast cancer research using novel antibody-drug conjugates. Geneva Principal Investigator Martin J. Schenermann, PhD, a senior investigator at the National Cancer Institute (NCI) and Principal Investigator Brad St. Croix, PhD, a senior scientist also at NCI, were each awarded
The USU-4DBio3 Center for Biotechnology, administered by The Geneva Foundation, ensures warfighters are supported by cutting-edge biotechnologies. BETHESDA, MD – The Geneva Foundation (Geneva) announces today the official designation of the Biotechnology, Biomanufacturing, and Bioprinting Program (4DBio3) as a Uniformed Services University (USU) Center. The USU-4DBio3 Center for Biotechnology, derived from the 4DBio3 Program
Kent Kester, MD, is appointed as SAB Chair. The Geneva Foundation (Geneva) announces today the appointment of four new members to its Scientific Advisory Board (SAB) which provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. “It is a great honor to take on the role
PREVIOUS GENEVA VICE CHAIR NEIL VINING, MD, MBA IS APPOINTED AS BOARD CHAIR. The Geneva Foundation (Geneva) announces changes to its Board of Directors with several new additions and the appointment of Dr. Neil Vining as Chair. The additions, and appointment of a new Chair, come as several long-serving members retired from the Board of Directors
LTC (P) Matthew Eckert, MD and CAPT Daniel Lammers, MD will present their research findings at the 34th East Scientific Assembly. During acute trauma scenarios, medical personnel are in a battle with time as the challenge becomes: is there enough time to stop ongoing blood loss? Hemorrhage from major trauma is the leading cause of death
Renowned lung injury Research Scientist Andriy Batchinsky, MD has been named The Geneva Foundation’s (Geneva) 2019 Researcher of the Year in recognition of his long-standing career pursuing ground-breaking treatments for the management of acute respiratory distress syndrome (ARDS), with notable contributions in research quality and research mentorship. Dr. Batchinsky is a principal investigator for Geneva and manager
ON-DEMAND BLOOD WILL ENABLE MILITARY MEDICAL PROFESSIONALS THE ACCESS TO QUALITY BLOOD SUPPLIES FROM ANYWHERE IN THE WORLD. The Geneva Foundation (Geneva) announces today the expansion of the 4-Defense Biotechnology, Biomanufacturing and Bioprinting Center (4D Bio3) program, a federally-funded partnership based at the Uniformed Services University (USU) and administered by Geneva, with the addition
HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO
A team of clinical and technical experts will provide urgently needed comprehensive solutions for clinical, informational, technical, training, and deployment aspects in order to bring critical care resources to every bedside. The Geneva Foundation (Geneva) and the Telemedical Research for Operational Support (TR4OS) program of Madigan Army Medical Center has been selected to create the
